RPG Life Sciences, a prominent pharmaceutical company, has significantly accelerated its expansion in the active pharmaceutical ingredients (API) business, investing a substantial ₹215 crore in two strategic acquisitions within just five weeks. This aggressive "buy-and-build" strategy aims to dramatically increase the company's scale, enhance its complex chemistry capabilities, and broaden its international presence.
Rapid Expansion Through Key Acquisitions
The recent acquisitions of Actis Generics for ₹85 crore and Raghava Life Sciences have transformed RPG Life Sciences' API platform. These moves have boosted manufacturing capacity from 110 KL to an impressive 505 KL. The company's API customer base has more than doubled, growing from 123 to over 250, while its product portfolio expanded from 14 to 45. Furthermore, the R&D pipeline has seen significant growth, increasing from 12 to 28 products, and the API workforce has expanded from 217 to over 500 employees.
According to Ashok Nair, Managing Director of RPG Life Sciences, the company established a dedicated API organization, RPG Active Pharma, and secured ₹243 crore from a healthcare-focused private equity investor, creating a committed investment pool of ₹700 crore for future growth.
Strategic Benefits of the Acquisitions
- Actis Generics: Added crucial manufacturing and backward-integration capabilities.
- Raghava Life Sciences: Contributed an approximately 300 KL manufacturing facility, 22 commercialized products, international approvals, and established customer relationships.
These acquisitions have evolved RPG Life Sciences from an API-only operation into a more robust, backward-integrated API and advanced intermediates platform.
Future Growth and Market Targets
RPG Life Sciences is actively evaluating further acquisitions and organic expansion initiatives, planning to deploy an additional ₹500-700 crore over the next 12 months. The focus remains on strengthening its manufacturing footprint, diversifying its product portfolio, and enhancing technical capabilities. The company expresses particular interest in acquiring a large manufacturing site, ideally one with existing USFDA approvals and a product portfolio complementary to its current operations.
The strategy emphasizes niche APIs involving difficult chemistry and multi-step synthesis, rather than commoditized products. This approach aims to leverage higher technical entry barriers, foster stronger customer loyalty, and reduce exposure to price erosion.
Current facility utilization rates vary, with the Navi Mumbai plant at 60% and Actis near full capacity. Raghava, however, is presently operating at only about 20% capacity, offering significant headroom for future growth. The company projects Raghava alone to generate around ₹200 crore in revenue once its utilization reaches 70-80%, with a target of 75-80% collective utilization across all three API manufacturing facilities.
Ambitious Revenue Goals and International Reach
The API expansion is integral to RPG Life Sciences' broader ambition to achieve approximately ₹2,500 crore in revenue by 2030. This target anticipates the domestic formulations business reaching ₹1,200 crore (from ₹700 crore), APIs contributing ₹500-700 crore, and international formulations accounting for the remainder.
Beyond APIs, the company is also widening its international footprint. With operations in over 60 countries, RPG Life Sciences is expanding into new markets such as Africa, Canada, Saudi Arabia, and Latin America. It expects to commercialize naproxen in Canada by February 2027 following regulatory approval.
Entering the GLP-1 Segment
A significant new venture for RPG Life Sciences is its planned entry into the rapidly growing GLP-1 segment, with a product launch slated for October. The company views this category as a crucial opportunity, especially given its established presence in niche specialties. Having partnered with a research innovator for this product, RPG Life Sciences aims to capture a share of India's GLP-1 market, which Nair anticipates will grow to approximately ₹4,000 crore over the next three to four years.
This strategic push for API growth complements the company's recent organic expansion, fueled by a stronger cash position and robust performance, enabling it to pursue inorganic opportunities while maintaining a focus on both revenue growth and profitability.